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Abstract
Goldnanoparticlescanbeconjugatedwith
antibodiesorotherproteins,andtheresulting
compositeparticleswillselectivelyattachtovarious
kindsofbiologicalmaterial.Althoughexploitationof
thisforstainingmicroscopyspecimensiswell
known,therehasrecentlybeeninterestinattaching
goldnanoparticlestolivecellsfortherapeutic
reasons.Onemotivationisthatgoldnanoparticles
displayastrongplasmonresonancewithlight,which
canbeexploitedinprincipleforan‘invivo’
photothermaltherapy.Thetreatmentofcancerby
thistechniquehasrecentlyreceivedattentionby
others,buthereweshowhowgoldnanoparticle-
basedtherapiescanbedevelopedtotargetlive
macrophagecells.Wehaveemployed‘active
targeting’,aschemeinwhichgoldnanoparticlesare
functionalisedwithanantibodyspecifictothetarget
macrophagecell.Wedescribehowtopreparethe
conjugatedparticles,demonstratethattheywill
selectivelyattach‘invitro’totheirtarget
macrophagecellbutnottoanon-targetcelltype
andshowthattheirpresencerendersthetargetcell
susceptibletodestructionbyalowpowerlaser.
1 Introductionandbackground
Nanoparticles of gold have a growing role in medical 
biotechnologies [1]. In particular, the pioneering development 
of immunogold labelling in 1971 [2] has inspired their use in 
many new diagnostic biological applications [3]. In these 
technologies the role of the gold is to enhance contrast and 
resolution in cellular samples examined in an electron 
microscope. More recently, however, the change in colour 
that occurs in gold nanoparticle sols on aggregation (or, 
rarely, de-aggregation [4]) has been used to obtain very 
sensitive assays for substances such as DNA [5] or, the 
pregnancy hormone chorionic gonadotrophin [6]. However, 
in all these instances the techniques are analytical in nature, 
and obviously applied only to ex situ material. Of course there 
has also been considerable in vivo use of gold, both colloidal 
[7] and soluble [8] in Chinese traditional medicine and in 
quack Western ‘medicine’ [9, 10]. Furthermore, the 
revolutionary work of Forestier in the 1930s set the scene for 
the use of soluble gold organo-metallic compounds for some 
types of rheumatoid arthritis [10, 11], and similar compounds 
appear to have some prospects for use in anti-cancer and 
anti-HIV treatment [10]. Radioactive gold nanoparticles have 
been used to treat certain cancers since the 1950s [12, 13] 
while ordinary gold nanoparticles can be used to enhance 
dosage in radiotherapy [14] and have been intensively 
investigated as possible drug delivery vectors [1]. It is apparent 
therefore that the usage of gold in medical applications has a 
respectable pedigree.
The particular interest in gold nanoparticles is motivated 
by their unique combination of properties. Three of these are 
paramount. First, the particles are resistant to oxide formation 
under ambient conditions, which permits direct engagement 
of the metallic gold surface with the surrounding environment. 
This permits the controlled attachment or detachment of 
organic molecules from the gold surface, as desired, by either 
exploiting the gold-sulphur bond or electrostatic attraction. 
Secondly, gold surfaces and gold nanoparticles have unusual 
optical properties, in particular surface plasmon polaritons 
and surface plasmon resonances respectively, which are in 
the visible range of the electromagnetic spectrum. Light 
absorbed by surface plasmon resonance is converted to heat, 
which can be exploited to deliver a very localised temperature 
increase. Finally, gold has a high atomic number, a feature 
which renders it readily detectable in electron microscopes 
or by X-rays. The various advantages of gold are neatly 
brought together in gold-protein conjugate particles, which 
are formed when gold nanoparticles are encapsulated with a 
coating of biological material such as a protein or antibody. 
The biological molecule may be bound to the gold by a 
covalent bond, or (more commonly) it is attached by 
electrostatic forces. In either event, gold-protein conjugates 
are finding broad application in cell biology in general [15], 
for example as a colorimetric probe for analyzing DNA [5], for 
protein microarrays [16], detection of GLUT1 in diabetic rats 
[17], pregnancy testing in humans [6], the detection of 
GoldBulletin2007•40/2 121
GOLD2006PRESENTATION
This work is licensed under a Creative Commons Attribution 3.0 License: http://creativecommons.org/licenses/by/3.0
GoldBulletin2007•40/2 122
The use of these particles in photothermal medical contexts 
is predicated upon two overarching principles. First it must be 
possible to introduce them into the patient in some way that 
avoids the body’s well-honed mechanisms for identifying, 
neutralizing and removing foreign objects and, secondly, they 
must become selectively localised in the desired target tissue 
which must also be within range of a suitable high intensity 
laser source. The immediate objective of the present research 
was to investigate the second principle, i.e. the methods 
by which gold nanospheres can be concentrated in specific 
live target tissues. Furthermore, while nanoparticles can 
be concentrated in many tumours by extravasation caused 
by enhanced permeability of the tumour vessels, or by 
simple filtration-induced retention (so-called ‘passive targeting’ 
[33]), these principles are not of general applicability. Instead 
we have employed active targeting [33, 34], in which 
gold nanoparticles are functionalised with an antibody specific 
to the target cell. The special feature of our work is 
that we have sought to target macrophage cells rather 
than cancer cells. Not only are macrophage-based malfunctions 
key events in auto-immune diseases such as atherosclerosis, 
diabetes or rheumatoid arthritis, but these cells are 
also frequently the host for parasitic organisms such as 
Toxoplasma gondii, Mycobacterium tuberculosis and Listeria 
monocytogenes [34]. Furthermore, these cells have the natural 
attribute of attacking and ingesting foreign material in the 
body anyway, making them an inviting target for nanoparticle- 
based therapies [34]. 
2 Experimental
The overall experimental methodology is summarised in 
Figure 2. Spherical gold nanoparticles are conjugated to 
conformational changes in proteins [18], diverse biosensors 
[19-22], and to enhance light scattering of targeted cell types 
in microscopy [23, 24].
However, while the uses of gold nanoparticles in diagnostic 
applications and of soluble gold compounds in therapeutic 
applications are now comparatively well known, the rational 
application of gold nanoparticles in therapeutic situations is a 
largely undeveloped field. It is this possibility that interests us. 
In Figure 1, we offer a classification of the existing and 
potential applications of gold nanoparticles in medical 
biotechnology, arranged in a taxonomy that is convenient for 
the present paper. The present article focuses on the branch 
shown in bold on the diagram, that is, the use of gold 
nanoparticles for photo-activated therapeutic possibilities. 
We have recently reviewed progress in this field [25] but since 
then, there have been several new developments [26-32]). In 
the present article, however, we focus strictly on gold-protein 
conjugates developed around spherical gold nanoparticles. 
There is no space here to comprehensively compare the pros 
and cons of nanospheres versus nanorods or shells in 
photothermally activated medical contexts. Suffice it to say 
that the spheres have a surface plasmon resonance in 
the mid-visible region of the spectrum (520 to 550 nm, green 
light) whereas rods and shells can be tuned to absorb at 
wavelengths from 600 to 1000 nm (red to near-infrared). 
However, the response of rods to conjugation with proteins 
is different to that of spheres. Not only are the former 
positively charged overall, compared to the negative charge 
on spheres, but they are usually stabilised with 
cetyltrimethylammonium bromide (CTAB), a powerful and 
cytotoxic surfactant, whereas gold nanospheres are usually 
stabilized with comparatively inert substances such as sodium 
citrate. Shells, on the other hand, have (so far) not been 
readily produced in large quantities.
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Classification of the biomedical uses of gold nanoparticles
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from the heater and stirred for a further 15 minutes. The sol 
was stored at 4oC.
2.2 Conjugationofgoldspheresandantibody
The approach used to conjugate the gold nanoparticles with 
antibody was based on previously published methods [3, 39]. 
In brief, the pH of the gold sol was adjusted to approximately 
7.5. Determination of the optimal gold-antibody concentration 
was achieved using the titration method. In this technique 
different concentrations of antibody are incubated with the 
gold nanospheres for 10-15 minutes at room temperature. 
Following the incubation, the lowest amount of antibody that 
stabilizes the gold nanoparticles was identified by adding 10% 
NaCl. The minimum concentration of antibody that did not 
exhibit a colour change from burgundy to blue was judged 
the most suitable amount for conjugation. The principle 
is that ordinary gold sols are stabilized by electrostatic 
repulsion between the positively charged nanoparticles. This 
is screened by the ions in the 10% NaCl so the sol aggregates 
(which makes it turn blue due to particle-to-particle dipole 
interactions). However, a correctly conjugated nanoparticle is 
stabilized by steric factors and therefore not sensitive to an 
increase in the ionic concentration of the solution. 
Two kinds of conjugate were prepared, one with bovine 
serum albumin (BSA) and a second with rat anti-mouse 
monoclonal antibody (CD11b-Mac1, Chemicon International, 
California, USA, designated hereafter as ‘CD11b’). In both 
cases the conjugation was carried out after first adjusting 
the pH of the sol to 7.5 using small additions of 0.5M KOH. 
The proteins were incubated with the sol for 10-15 min, 
after which unbound antibody or protein in the supernatant 
was removed by centrifugation at 13000 rpm, +4oC, for 25 
minutes, followed by washing in phosphate saline buffer (PBS; 
no Ca2+ or Mg2+). The antibody- or BSA-conjugated gold pellet 
was then re-suspended in PBS plus 1% bovine serum albumin 
(BSA). The absorbance of the working solution was adjusted 
to 0.6 at 530 nm by dilution. 
Protein analyses were done by the bicinchoninic acid 
method (BCA protein assay). Briefly, 10 μl of supernatant was 
CD11b, an antibody specific to the murine macrophage cells 
that we have used as our model target. The cell cultures are 
then exposed to the gold-antibody conjugates, which bind to 
the outer membranes of the target cells. Following this the 
nature of this binding is investigated using electron backscatter 
mode in a scanning electron microscope and, after attaching 
a fluorescent-tagged secondary antibody to the conjugate, 
with confocal optical microscopy. Photothermal destruction 
of the targeted cells is accomplished by irradiating with a laser 
at a wavelength that induces plasmonic heating in the gold 
nanoparticles. We investigated the behaviour of ‘naked’ gold 
nanoparticles (ie. citrate-stablized particles without attached 
antibody) and confirmed that they also bound to some extent 
to live cells, a fact already recorded in the literature [35, 36] 
although they do so to a far lesser degree than if conjugated 
with a specific antibody [37, 38]. Nevertheless, this rendered 
the naked gold particles useless as a negative control in the 
present work. On the other hand, we found that conjugates of 
gold with bovine serum albumin (BSA) demonstrated greatly 
reduced levels of non-specific binding to the cells. Therefore 
gold-BSA conjugates were prepared as one of the controls. In 
addition, the far lower cost of BSA provided an opportunity to 
investigate the conjugation process in more detail than was 
feasible with the CD11b antibody. 
The following sub-sections provide detail of the 
experimental procedures. 
2.1 Preparationofgoldspheres
The preparation of the gold nanospheres followed the 
standard citrate-reduction route. All glassware used was 
cleaned in aqua regia (3 parts of concentrated HCl plus to one 
part of concentrated HNO3) before use. HAuCl4.3H20 (1mM) 
was used as a starting solution. This was transferred to a 250 
ml conical flask for heating and stirred vigorously. When its 
temperature reached 90oC, 10 ml of 38.8 mM sodium citrate 
was quickly added. A blue colour immediately developed 
which changed shortly thereafter to the well-known deep 
burgundy of gold nanosphere sols. Heating continued for 
another 15 minutes after which the solution was removed 
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Figure2
Schematic illustration of methods by which gold nanoparticles were attached to target cells and characterized
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mixed with 200 μl working reagent ( BCA Reagent A and B, 
Pierce, USA) by shaking for 30 seconds. The mixed solution 
was then incubated at 37oC for 30 minutes after which the 
absorbance at 560 nm was measured on a microplate reader. 
A standard solution of 1mg/ml BSA was used for calibration. 
Unfortunately, protein analysis of the gold pellet could not 
be reliably undertaken due to interference from the colour 
of the colloid itself.
2.3 Cellpreparationandlabelling
Murine macrophage cells (Raw 264.7) and Chinese hamster 
ovary cells (CHO-K1) were cultured on glass cover slips in 
Dulbecco’s modified Eagle’s medium/Ham’s nutrient mixture 
F-12(DMEM-F12, JRH Biosciences) including 2 mM glutamine 
supplemented with 10% fetal bovine serum (FBS, JRH 
Bioscience). Cells were seeded onto glass coverslips at 1x105 
cells/ml and maintained in a humidified incubator at 37oC and 
5% CO2 for 48 hours. Labelling of the cells was accomplished 
by incubating them with gold-antibody conjugates in PBS 
plus 1% BSA for 1 hour at 37oC and under 5% CO2, and 
washed four times with PBS plus 1% BSA to remove unbound 
gold-antibody conjugates. Negative controls included the 
incubation of gold-BSA conjugates with the macrophage 
cells, and the incubation of gold-CD11b conjugates with the 
CHO-K1 cells.
2.4 Microscopy
Cells labelled with gold spheres (as outlined above) were fixed 
with 4% paraformaldehyde in PBS for 25 minutes at room 
temperature. For optical microscopy the cells were then 
incubated with a secondary FITC (fluorescein isothiocyanate) 
antibody (goat anti-rat IgG-FITC; Sigma-Aldrich, MO, USA, 
designated hereafter as ‘2oabFITC’) at a dilution of 1:30 
for 1 hour at 37oC. Cells were washed four times with PBS 
to remove unbound secondary FITC and viewed under a 
confocal microscope (FV300, Olympus). The purpose of the 
secondary antibody, which is fluorescent, was to provide 
a clear visualization of the location of all active CD11b 
antibodies. To observe endocytosis of gold nanoparticles by 
the macrophage cells, an experiment was done as above but 
without fixation.
For scanning electron microscopy the cells were fixed as 
described before, then washed four times with PBS and six 
times with Milli-Q water. The cover slips were then dried and 
stored in a desiccator until imaged.
2.5 Irradiationbylaser
The mature murine macrophage cells were incubated 
with conjugated and unconjugated gold nanoparticles. 
Following this the cells were irradiated for 10 minutes by a 
543.5 nm green HeNe laser with a core size (determined 
using laser burn paper) of 0.1 mm (although to the eye 
the spot size appeared closer to 2 mm). The power of 
the laser was measured to be ~2.5 mW using a power 
meter. Thereafter, the cells were incubated for an hour at 
37oC and their viability checked by using SYTOX green nucleic 
Figure3
Basic citrate-stabilized gold nanospheres on which the conjugation were based. (a) Image of unconjugated gold nanospheres taken using an electron 
microscope, (b) Optical extinction of colloidal suspensions showing plasmon peak at ~526 nm and the red-shifting  effect of conjugation with proteins 
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Figure4
Concentration gradient of BSA/gold nanoparticle mixtures. The three 
tubes on the left contain insufficient BSA to stabilize the colloid when 
concentrated NaCl solution is added. The optimum concentration of 
BSA is that of the fourth tube. The fifth and sixth tubes contain excess 
BSA that must be removed by centrifugation and washing
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acid stain (Invitrogen, California, USA). Macrophages were also 
incubated with gold-BSA conjugates as the negative control.
3 Results
3.1 Gold-proteinconjugates
The citrate-stabilised gold nanoparticles and their optical 
extinction spectrum are illustrated in Figure 3. The particles 
have a nominal diameter of ~20 nm (Figure 3a) and are well 
dispersed while in colloidal suspension (as attested to by their 
optical spectra which showed an absorption peak at 526 
nm, Figure 3b). Conjugation of the particles with the BSA 
was straightforward, and a clear-cut transition from stable to 
unstable conditions achieved at a BSA/Au mass ratio of close 
to 1 (Figure 4). However, protein analyses of the supernatant 
fluid showed that, even under these supposedly optimum 
conditions, approximately 90% of the added BSA was actually 
present in the supernatant, with only 10% actually bound 
to gold nanoparticles. This excess protein was removed 
by the centrifugation and wash cycle, after which the pellet 
was resuspended. 
The surface loading of BSA onto citrate-stabilised gold 
nanoparticles has been measured by Brewer et al. [40] and 
by De Roe et al. [41] who established that complete coverage 
is associated with between 3.7x1012 and 6.2x1012 molecules 
per cm2. The molecular weight of BSA is of the order of 
66x103 daltons, so such a complete monolayer coverage 
on a monodispersed population of 20 nm diameter gold 
nanospheres would give a BSA:Au mass ratio of between 
0.06 and 0.10. As mentioned, our measurement was in the 
vicinity of 0.10. This corresponds to about 74 BSA molecules 
associated with each nanoparticle (since an individual BSA 
molecule has a mass of about 1.096x10-16 mg and an individual 
gold nanosphere of 20 nm diameter a mass of 8.08x10-14 mg). 
The size of a BSA molecule is variously given as 5 x 5 x 5 nm 
[42] or 5.5 x 5.5 x 9 nm [40] from which it can be estimated 
that around 40 to 50 BSA molecules would be required to form 
a monolayer on the gold nanoparticle. Either way, the figures 
are in reasonable agreement with our experimental results, 
given that some free BSA is still likely to be present in the pellet, 
that the protein analyses had limited accuracy, and, finally, that 
the gold particles were not actually monodisperse.
A less clear-cut transition was obtained when conjugating 
with the CD11b antibody compared with gold-BSA conjugates. 
In this case, the molecular weight of CD11b antibody (about 
170 KDa) is larger than BSA (66KDa) resulting in far fewer of 
the more bulky CD11b molecules being attached to each 
gold nanoparticle. The optimum concentration of CD11b was 
in the vicinity of 0.3 mg/ml. Calculations indicated that, on 
average, of the order of four or five CD11b molecules were 
attached to each gold nanoparticle. The plasmon resonance 
of the particles was slightly red-shifted after conjugation with 
either BSA or CD11b (see Figure 3b).
Figure5
Fluorescent (left) and transmitted light (right) images of various samples of live cells. (a) macrophage (Raw 264.7) cells incubated with gold and CD11b, 
(b) macrophage cells incubated only with gold/BSA conjugates followed by exposure to 2oabFITC, (c) macrophage cells incubated with 2oabFITC only, 
(d) CHO-K1 cells incubated with gold/CD11b conjugates, followed exposure to  2oabFITC  (e) macrophage cells plus Au/CD11b conjugates followed by 
exposure to 2oabFITC, (f) macrophage cells incubated with CD11b followed by exposure to 2oabFITC 
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3.2 Selectiveattachmenttolivecells
As hoped, the gold-CD11b conjugates bound to the 
macrophage cells but not to the CHO-K1 cells. The 
distribution of gold nanoparticles on the surface of cells was 
seen as bright spots by using scanning electron microscopy 
in backscatter mode. In contrast, there were no or few bright 
spots on macrophage cells not incubated with gold-antibody 
conjugates, or on the CHO cells. 
More detail was obtained when the cells were examined in 
a confocal optical microscope. In order to visualise the gold-
CD11b stained cells, a secondary anti-mouse FITC conjugate 
was used. In this case fluorescent staining was observed 
around the periphery of macrophage cells (Figure 5e) that had 
been incubated with the gold-CD11b antibody conjugates. 
As expected, no fluorescence staining was noted in the 
samples lacking secondary FITC antibody (Figure 5a). Similarly, 
CHO-K1 cells stained with the gold-CD11b followed by the 
secondary FITC conjugate showed no fluorescent staining 
(Figure 5d), indicating that the gold-CD11b conjugate had 
no affinity for these cells. Similarly incubating the RAW cells 
with the secondary FITC antibody alone also did not cause 
any fluorescent staining (Figure 5c). To confirm the normal 
staining pattern of CD11b, macrophage cells were stained 
with this antibody followed by exposure to the secondary 
antibody. These cells demonstrated the same strong staining 
of the cell periphery (Figure 5f) as was seen for the gold-
CD11b conjugates (Figure 5e). Finally, macrophage cells 
were exposed to gold-BSA conjugates and then incubated 
with the secondary antibody. No staining took place in this 
case (Figure 5b). 
In another experiment the RAW cells were incubated with 
CD11b / FITC conjugated gold nanoparticles for a period 
of one hour. This time is sufficient to allow the process of 
endocytosis (the process by which many cells engulf and 
ingest external macromolecules or particles) to occur. The 
Figure6
Macrophage cells that have been incubated with gold –CD11b and 
2oabFITC particles for one hour. The gold particles appear to have 
been taken up into the cells by endocytosis, and a proportion of them 
are visible as granular green concentrations within the cell. These 
concentrations presumably correspond to the lysosomes that are 
encapsulating the particles which are still fluorescent (eg. Shukla  
et al.[36])
Figure7
Effect of laser irradiation on cells treated with various types of gold nanoparticles. The dead cells glow green under the fluorescent mode of the confocal 
microscope. Top row, no irradiation, bottom row, after irradiation with a HeNe green laser at a wavelength 543.5 nm for 10 minutes. (a & e) Cells only, 
no gold, (b & f) cells incubated with naked gold nanoparticles, (c & g) cells incubated with gold-BSA conjugates, (d & h) cells incubated with gold-CD11b 
antibody conjugates
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result is shown in Figure 6. Close examination of that figure 
indicates that the FITC dye (and hence presumably the 
gold nanoparticles to which it was bound) is present on the 
surface of the cells, and also in patchy regions within them. 
The usual process with macrophage cells is that they take 
up foreign material by endocytosis, in the process of which 
the material is encapsulated in a lysosome within the 
cytoplasm. The patchy appearance of dye within the cells 
is compatible with this possibility, which has also been 
suggested by others [36].
These results demonstrate that the CD11b antibody 
conjugated to gold nanospheres bound selectively to its 
target macrophage cells and was internalized by them. This 
event did not take place to any significant extent in the CHO-
K1 cells. Similarly, the control gold-BSA / FITC conjugates did 
not demonstrate significant binding or internalization to the 
macrophage or CHO-K1 cells.
3.3 Laserirradiationofcells
The effect of irradiating the macrophage cells with and 
without the various kinds of gold nanoparticles is shown 
in Table 1 and Figure 7. After staining with SYTOX green 
dye, negligible cell death was observed in the samples not 
exposed to laser irradiation. Negligible cell death was also 
demonstrated in samples that had not been pre-treated with 
gold nanoparticles conjugated with antibody but that were 
then exposed to laser irradiation at the same laser fluencies 
and the same exposure time. In contrast, the death rate 
for cells that had been pre-incubated with gold-antibody 
conjugate followed by laser irradiation was found to increase 
to at least 25%. It is evident from this result that photothermal 
heating of the gold nanoparticles strongly affects cell viability 
of target cells. In fact the percentage of dead cells is likely 
to have been higher than what is reported here, given that 
the laser has a Gaussian distribution of intensity and the area 
counted under the microscope (2 mm diameter) exceeded 
the zone of maximum laser intensity (~0.1 mm diameter). 
Macrophage cells pre-incubated with naked gold showed 
very low levels of cell death (~1%), indicating that there was 
negligible non-specific binding of the gold particles to the 
cells. A similar result was achieved in cells pre-incubated with 
gold-BSA conjugates, showing an even lower death rate of 
0.61% following laser exposure. These results further confirm 
that cells exposed to laser irradiation with no bound gold 
were not susceptible to the energy of the laser. These results 
are statistically significant and demonstrate the principle of 
specific cell targeting and targeted cell death.
4 Discussion
This paper has focused on the preparation and characterization 
of a gold-antibody conjugate that selectively binds to a live 
macrophage cell line, which then allows for the selective 
photothermal destruction of the target cell. It is however 
well worth discussing the therapeutic directions that this 
capability might head towards, of which there are two 
significant possibilities:
In the first scenario the gold-antibody conjugates are bound 
to, or taken up by, the target cell, and then laser illumination 
at a suitable wavelength is applied to the relevant region of 
the patient. The particles will then absorb the radiation and 
heat up. The gold-antibody conjugates themselves would 
have to be introduced intravenously into the patient, and 
there are some practical difficulties that might be expected. 
However, there has already been considerable progress 
made in respect to passively targeting cancer cells by such 
means e.g. [14, 43, 44], with some encouraging reports 
involving active targeting of cancer cells e.g. [23, 31, 45] and, 
rather more rarely, reports of other target organisms such 
as bacteria, rather than eukaryotic cells [37]. If pulsed laser 
radiation is applied, then comparatively high laser intensities 
are required to produce a lethal temperature change of, for 
example, 15oC, in the vicinity of the gold particles. However, 
Table1
Cell death rates with and without gold-protein conjugate particles and laser irradiation 
 Treatment C CL CG CGL CGBSA CGBSAL CGAb CGAbL
 Percentage of dead cells- 0.46 0.11 0.76 1.35 0.23 0.61 0.80 25.42
 Standard deviation (%) ± 0.46 ± 0.61 ± 0.82 ± 0.95 ±0.33 ±0.58 ±0.54 ±6.26
 Total number of 
 counted cells (n) 6544 5406 6198 4669 3047 980 3506 2030
Key
C = Only macrophages 
CL = Macrophages exposed with a laser
CG = Macrophages attached with naked gold nanoparticles
CGL= Macrophages attached with naked gold nanoparticles and exposed with a laser
CGBSA = Macrophages attached with gold-BSA conjugates
CGBSAL =  Macrophages attached with gold-BSA conjugates and exposed with a laser
CGAb = Macrophages attached with gold-CD11b antibody conjugates
CGAbL = Macrophages attached with gold-CD11b antibody conjugates and exposed with a laser 
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in this paper, we have used a continuous wave radiation 
from a green laser at wavelength 543.5 nm, applied for a 
few minutes. A similar effect was also produced using far 
lower intensities of radiation with a laser power value of 2.5 
mW, but applied for longer times. The gold nanoparticles 
strongly absorbed light from the laser due to the overlapping 
of surface plasmon absorption band between the laser 
(543.5 nm) and gold nanoparticles (526 nm). This light 
absorption by the gold nanoparticles is then converted into 
heat by electron-phonon and phonon-phonon processes [46] 
resulting in the destruction of targeted cells The important 
criterion, it seems, is that a fluence of at least 1 J/cm2 be 
delivered [47]. In either case the desired outcome is death of 
the target cell by hyperthermia. Of course, the survivability 
of individual cells when challenged by a rise in temperature 
will exhibit some statistical variation, and similarly there is a 
source of variation due to the fact that individual cells might 
have different numbers of gold particles attached. However, 
in contrast, control macrophage cells that did not have 
attached gold nanoparticles demonstrated no hyperthermal 
mortality when irradiated by laser, probably because of the 
near-transparency of the natural endogenous cytochromes 
at the wavelength used [37].
It will obviously be important to further characterise the 
energy threshold required to kill a cell. This depends on the 
power density arising from the laser light, on the number of 
gold particles on the surface of the cell, and the individual 
properties of the specific cell type. In the current experiments 
a relatively low power density laser was used, resulting in about 
25% cell death. Use of a higher power density would result in 
an increased number of dead cells in a given time [48], or a 
similar death rate can be obtained but with a smaller number 
of gold particles attached to each cell or the same density 
of gold nanoparticles but a shorter exposure time. The use 
of gold nanoparticles provides new flexibility which might 
overcome the side effects of conventional photodynamic 
therapy based on the light activation of dyes [49].
The second scenario in which the phenomena described 
could be exploited is more subtle. In this instance the desired 
effect is that the gold-organic conjugate enters the target cell, 
either through a temporarily permeablized cell membrane, 
or by the naturally occurring process of endocytosis. The 
payload in this case is not necessarily hyperthermia, but 
could also be the organic component conjugated to the gold 
nanoparticle, for example tumour necrosis factor (TNF) [13] 
or even genetic material [1]. Either way, a gold nanoparticle 
conjugate provides a convenient vehicle for delivery, and low 
power plasmonic heating of the gold nanoparticle might 
additionally provide the means either to permeabilize the 
cell membrane and/or to liberate a molecular payload [13, 
26, 28, 44, 45, 50]. Macrophage cells can act as host cells 
for some pathogenic microorganisms [34] and temporary 
permeabilization of their membranes to permit the ingress 
of some large drug molecules could be useful. Alternatively, 
the scheme could be developed to deliver gene transfection 
or gene therapy.
Finally, it may be worth commenting on an apparent 
anomaly, also noted by others in the literature [40]. The 
isoelectric point of BSA is 4.6, so it would be negatively 
charged at a pH of greater magnitude. Secondly, it is well-
established that proteins prefer to bind to a surface of 
opposite charge. [42]. Unfortunately, citrate-stabilized Au 
nanoparticles are also negatively charged (-40 to -50 mV 
depending on pH [13, 40]). So how is it possible that the 
protein is bound to the gold at neutral values of pH? Brewer 
et al. [40] postulate that it was actually surface lysine groups 
in the BSA that bound to the Au, overcoming the overall 
unfavourable charge distribution on the protein. This point 
has a direct bearing on the conjugation process and probably 
deserves more attention in future.
5 Conclusions
Gold nanoparticles have been functionalised with an 
antibody against a particular macrophage cell, and the 
resultant conjugated particles show selective binding to their 
live target. Selective destruction of the target cell line is then 
possible by applying laser irradiation with a laser tuned to 
the plasmon resonant frequency of the gold nanoparticles. 
Availability of these particles and wider knowledge of their 
properties should facilitate the development of actively-
targeted photothermal therapeutic treatments. 
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